Adela Health

Adela is a biotechnology company specializing in the development of blood-based tests for the early detection of cancer and other high-morbidity diseases. The company's proprietary platform utilizes a highly sensitive methylome analysis technology known as cfMeDIP-seq to profile cell-free DNA. This approach allows for the detection of low-abundance cancer signals by focusing on the "dark matter" of the genome, providing a more comprehensive view than traditional mutation-based liquid biopsies. Adela's lead programs are focused on multi-cancer early detection (MCED) and minimal residual disease (MRD) monitoring across various oncology indications. Headquartered in Foster City, California, the company was founded on technology developed at the University Health Network's Princess Margaret Cancer Centre. Adela is backed by a syndicate of leading life science investors, including F-Prime Capital and OrbiMed, to advance its clinical validation studies and commercialize its diagnostic portfolio.